Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 18, 2021 | May 20, 2021 |
| Rivian Automotive, Inc. / DERIVN · Entity 3226 | Director | June 22, 2026 | June 23, 2026 |
| Senti Biosciences Holdings, Inc.DYNS · Entity 7935 | Director | May 25, 2021 | May 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,628 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 22,628 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 336,313 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 336,313 F3: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee.
F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
ILLUMINA, INC.
Report date May 18, 2021 · Filed May 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,933 |
Reported balance
After 2021-05-18 transaction · row 1
1 source rowRow 1 · 2021-05-18 · Sale · Disposed 4,000 · Balance 148,933 F1: The sale was made pursuant to a 10b5-1 plan. |
| Common StockSEC Table I · non-derivative | IndirectBy Daughters | 3,500 |
Reported balance
Holding disclosure · report date 2021-05-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was made pursuant to a 10b5-1 plan.
Rivian Automotive, Inc. / DE
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 179,515 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 17,445 · Balance 179,515 F1: Represents an award of 17,445 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 17,445 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date.
Senti Biosciences Holdings, Inc.
Report date May 25, 2021 · Filed May 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | IndirectSee footnote | 10,733 |
Reported balance
Holding disclosure · report date 2021-05-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,733 F1: Up to 900 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus"). F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers. |
| Class B common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2021-05-25 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date. F4: Up to 4,894 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus. F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers. |
Filing footnotes · ownership attribution and instrument terms
F1: Up to 900 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus").
F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers.
F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date.
F4: Up to 4,894 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COHERENT INC
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 43,018 · Balance 0 F1: On July 1, 2022, II-VI Incorporated ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Watson Merger Sub Inc, a direct, wholly owned subsidiary of Buyer ("Merger Sub"), dated as of March 25, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $220.00 in cash, without interest (the "Cash Consideration"), plus 0.91 of a validly issued, fully paid and nonassessable share of Buyer (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: On July 1, 2022, II-VI Incorporated ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Watson Merger Sub Inc, a direct, wholly owned subsidiary of Buyer ("Merger Sub"), dated as of March 25, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger (the "Merger").
F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $220.00 in cash, without interest (the "Cash Consideration"), plus 0.91 of a validly issued, fully paid and nonassessable share of Buyer (the "Merger Consideration").
Juno Therapeutics, Inc.
Report date March 05, 2018 · Filed March 07, 2018
Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Flatley Family Trust | 0 |
Reported balance
After 2018-03-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-03-05 · Other · Disposed 31,500 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2027-05-21 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-05 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2027-06-15 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.
Zymergen Inc.
Report date October 19, 2022 · Filed October 20, 2022
Section 16 reporting ended · disclosed 2022-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 1
1 source rowRow 1 · 2022-10-19 · Disposition to issuer · Disposed 144,789 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $12.33 · Expires 2031-08-06 | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-19 · Disposition to issuer · Disposed 1,520,000 · Balance 0 F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.52 · Expires 2029-09-17 | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-19 · Disposition to issuer · Disposed 189,125 · Balance 0 F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo.
F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2020 Filed Dec 16, 2020 23:07 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $348.84 | $1,395,360.00 |
DisclosureSEC source: 0001127602-20-031603 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 22:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,000 | $324.01 | $324,010.00 |
DisclosureSEC source: 0001127602-20-030336 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 22:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,000 | $323.86 | $971,580.00 |
DisclosureSEC source: 0001127602-20-030336 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,000 | $298.01 | $298,010.00 |
DisclosureSEC source: 0001127602-20-029566 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 2,000 | $296.73 | $593,460.00 |
DisclosureSEC source: 0001127602-20-029566 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:43 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,000 | $298.01 | $298,010.00 |
DisclosureSEC source: 0001127602-20-028129 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:43 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 2,000 | $297.00 | $594,000.00 |
DisclosureSEC source: 0001127602-20-028129 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 19:47 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,000 | $324.01 | $324,010.00 |
DisclosureSEC source: 0001127602-20-027412 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 19:47 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,000 | $320.95 | $962,850.00 |
DisclosureSEC source: 0001127602-20-027412 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,000 | $324.01 | $324,010.00 |
DisclosureSEC source: 0001127602-20-026718 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 20:49 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,000 | $317.79 | $953,370.00 |
DisclosureSEC source: 0001127602-20-026672 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:59 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $355.22 | $1,420,880.00 |
DisclosureSEC source: 0001127602-20-025304 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 23:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $355.35 | $1,421,400.00 |
DisclosureSEC source: 0001127602-20-024655 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:14 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $354.03 | $1,416,120.00 |
DisclosureSEC source: 0001127602-20-023993 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 21:54 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $397.73 | $1,590,920.00 |
DisclosureSEC source: 0001127602-20-022958 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:46 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $399.00 | $1,596,000.00 |
DisclosureSEC source: 0001127602-20-021969 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:52 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $370.22 | $1,480,880.00 |
DisclosureSEC source: 0001127602-20-021291 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $354.93 | $1,419,720.00 |
DisclosureSEC source: 0001127602-20-019912 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:00 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034766 · doc4.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Underlying: Common Stock · 3,253 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F3 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:00 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 15,183 | $0.00 Strike: $28.82 | $0.00 |
DisclosureSEC source: 0001209191-20-034766 · doc4.xml · derivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 Underlying: Common Stock · 15,183 shares Expires 2030-06-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $364.40 | $1,457,600.00 |
DisclosureSEC source: 0001127602-20-018728 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,933 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| May 27, 2020 Filed May 28, 2020 22:05 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 963 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018081 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,933 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 19, 2020 Filed May 20, 2020 22:48 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,000 | $342.34 | $1,369,360.00 |
DisclosureSEC source: 0001127602-20-017421 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,970 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:57 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,000 | $310.37 | $931,110.00 |
DisclosureSEC source: 0001127602-20-015822 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,970 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 17:29 UTC | COHERENT INC COHR · Entity 125737 | GrantCommon Stock | 2,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005257 · edgar.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,148 F1 · shares: On April 27, 2020 the Reporting Person was granted 2,148 Restricted Stock Units which will vest on February 15, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through this vesting date Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:52 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,000 | $310.77 | $932,310.00 |
DisclosureSEC source: 0001127602-20-014313 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,970 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 21:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 2,000 | $284.63 | $569,260.00 |
DisclosureSEC source: 0001127602-20-013508 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,970 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:03 UTC | COHERENT INC COHR · Entity 125737 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $44.74 | $0.00 |
DisclosureSEC source: 0001179110-20-003643 · edgar.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:03 UTC | COHERENT INC COHR · Entity 125737 | Exercise / conversionCommon Stock | 24,000 | $44.74 | $1,073,760.00 |
DisclosureSEC source: 0001179110-20-003643 · edgar.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Family Trust Disclosed balance after: 40,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects 25,805 shares transferred from direct ownership to the trust. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 21:31 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 2,000 | $277.40 | $554,800.00 |
DisclosureSEC source: 0001127602-20-009412 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,970 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| February 18, 2020 Filed Apr 8, 2020 21:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,000 | $299.00 | $897,000.00 |
DisclosureSEC source: 0001127602-20-013508 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,970 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 446 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-001116 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,970 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the date of the annual meeting of the company's stockholders in the year of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 21:59 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 3,015 | $320.57 | $966,518.55 |
DisclosureSEC source: 0001127602-19-034877 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,524 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,194 | $300.87 | $359,238.78 |
DisclosureSEC source: 0001127602-19-032188 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,539 Read SEC document |
| August 28, 2019 Filed Aug 29, 2019 20:33 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $283.41 | $935,253.00 |
DisclosureSEC source: 0001127602-19-027571 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,733 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 22:31 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $288.36 | $951,588.00 |
DisclosureSEC source: 0001127602-19-026807 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,033 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · balance_after: Balance includes 17 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| July 24, 2019 Filed Jul 25, 2019 21:22 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $304.00 | $1,003,200.00 |
DisclosureSEC source: 0001127602-19-025211 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,316 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 22:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $376.50 | $1,242,450.00 |
DisclosureSEC source: 0001127602-19-024498 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,616 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:06 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $358.15 | $1,181,895.00 |
DisclosureSEC source: 0001127602-19-023010 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,916 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:00 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $334.53 | $1,103,949.00 |
DisclosureSEC source: 0001127602-19-021629 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,216 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| May 30, 2019 Filed May 31, 2019 22:36 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,245 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-19-033738 · doc4.xml · derivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,245 Underlying: Common Stock · 27,245 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| May 22, 2019 Filed May 24, 2019 21:22 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $304.44 | $1,004,652.00 |
DisclosureSEC source: 0001127602-19-019947 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,516 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $318.59 | $1,051,347.00 |
DisclosureSEC source: 0001127602-19-018195 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,816 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $321.96 | $1,062,468.00 |
DisclosureSEC source: 0001127602-19-016350 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,116 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · balance_after: Balance reflects reduction of 39,252 shares which were previously inadvertently included in total. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 20:33 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $317.01 | $1,046,133.00 |
DisclosureSEC source: 0001127602-19-015330 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,668 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 20:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $306.93 | $1,012,869.00 |
DisclosureSEC source: 0001127602-19-013592 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,968 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| March 13, 2019 Filed Mar 29, 2019 20:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $306.50 | $1,011,450.00 |
DisclosureSEC source: 0001127602-19-013592 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,268 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 16:26 UTC | COHERENT INC COHR · Entity 125737 | GrantCommon Stock | 1,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002887 · edgar.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,805 F1 · shares: On February 28, 2019 the Reporting Person was granted 1,805 Restricted Stock Units which will vest on February 15, 2020, subject to the Reporting Person's continuing in service on the Issuer's Board of Directors through this vesting date. F2 · balance_after: Reflects 916 shares transferred from direct ownership to the trust. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:23 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $300.00 | $990,000.00 |
DisclosureSEC source: 0001127602-19-009270 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,568 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 21:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $293.66 | $969,078.00 |
DisclosureSEC source: 0001127602-19-005997 · form4.xml · nonDerivative · entry 4 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,868 F3 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · balance_after: Balance includes 62 shares acquired through Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.